Bayer

Venous Blood Clot Prevention after Hip or Knee Replacement Surgery: U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer’s rivaroxaban

An Advisory Committee to the U.S. Food and Drug Administration met today to discuss the new drug application for Bayer’s rivaroxaban, a novel, oral anticoagulant taken as one tablet, once-daily for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.

Most read

Latest

^